corner
Healthy Skepticism
Join us to help reduce harm from misleading health information.
Increase font size   Decrease font size   Print-friendly view   Print
Register Log in

Healthy Skepticism Library item: 18230

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

 

Publication type: news

Mack J
Sex, Pharmaceuticals, and Selling Sickness: I'm Looking Forward to a Great Time In Amsterdam!
Pharma Marketing Blog 2010 Jun 18
http://pharmamkting.blogspot.com/2010/06/sex-pharmaceuticals-and-selling.html


Full text:

This October I will be in Amsterdam enjoying the sights and pleasures that city has to offer. But I am not planning to buy sex or to smoke pharmaceutical substances. I do plan, however, to attend and make a presentation at the Selling Sickness conference hosted by Healthy Skepticism (Netherlands), assisted by the Dutch Institute for Rational Use of Medicine and Healthy Skepticism (International). The sponsors include the Dutch Ministry of Health and the Dutch Health Care Inspectorate. You can find the program here.

I look forward to this conference because “Female sexual dysfunction will be used as a case study to explore problems with disease promotion as well as policy options.” Ray Moynihan, journalist, co-author of the book “Selling Sickness: How The World’s Biggest Pharmaceutical Companies Are Turning Us All Into Patients” and author of “Sex, Lies & Pharmaceuticals,” is a featured speaker.

In preparation for the conference, I am following closely the news about flibanserin, a new drug developed by the German pharma company Boehringer Ingelheim (BI) for “hypoactive sexual desire disorder” (HSDD) in pre-menopausal women. Today, an FDA advisory committee will meet to review this drug’s application for marketing approval. BI must answer the question FDA always asks: is the drug safe and effective. The FDA’s own review, out yesterday, says the overall response rate in clinical trials isn’t “particularly compelling,” reports the WSJ Health Blog.

Perhaps an even more interesting question is whether or not hypoactive sexual desire disorder is a real medical condition. FDA does not consider that question when approving drugs. Whatever compound comes their way for which a drug company has clinical data, FDA’s only duty is to consider if it is safe and effective for whatever “condition” it is designed to treat. A drug company is free to invent a medical condition and FDA can’t say a word about that.

Do pharma companies “invent” medical conditions in order to sell drugs? Is hypoactive sexual desire disorder an “invented” medical condition?

One case where there is “smoking gun” evidence of a medical condition being invented by a pharma company is “overactive bladder,” another condition affecting mostly women. “Pharmacia instrumental in creating new disease,” said a marketing VP in the notes to his PowerPoint presentation made at an industry conference in October, 2002 (see Overactive Bladder: “Pharmacia instrumental in creating new disease” says Former VP).

My fellow blogger, Rich Myer, reviewed all the PR that BI is doing to create awareness of hypoactive sexual desire disorder: “In the last month, Boehringer has been trying to lay the consumer groundwork with a promotional campaign about women’s low libido, including a Web site, a Twitter feed, a Discovery Channel documentary and a publicity tour by Lisa Rinna, a soap opera star and former Playboy model, who describes herself as someone who has suffered from a disorder that Boehringer refers to as a form of ‘female sexual dysfunction.’” In his post Rich quotes Dr. Adriane Fugh-Berman, an associate professor at Georgetown University’s medical school: “This is really a classic case of disease branding,” said Fugh-Berman. “The messages are aimed at medicalizing normal conditions, and also preying on the insecurity of both the clinician and the patient.”

Oh, Oh, Rich! You are not in command of the facts. You should have read BI’s “Key Facts on HSDD and Flibanserin”. One fact cited is this: “HSDD is a medical condition – not simply ‘low libido.’”

Anyway, this is sure to be a BIG topic for discussion at the Selling Sickness conference in Amsterdam. I wonder if people from BI will be there or invited to speak? Hope so.

 

  Healthy Skepticism on RSS   Healthy Skepticism on Facebook   Healthy Skepticism on Twitter

Please
Click to Register

(read more)

then
Click to Log in
for free access to more features of this website.

Forgot your username or password?

You are invited to
apply for membership
of Healthy Skepticism,
if you support our aims.

Pay a subscription

Support our work with a donation

Buy Healthy Skepticism T Shirts


If there is something you don't like, please tell us. If you like our work, please tell others.

Email a Friend








Cases of wilful misrepresentation are a rarity in medical advertising. For every advertisement in which nonexistent doctors are called on to testify or deliberately irrelevant references are bunched up in [fine print], you will find a hundred or more whose greatest offenses are unquestioning enthusiasm and the skill to communicate it.

The best defence the physician can muster against this kind of advertising is a healthy skepticism and a willingness, not always apparent in the past, to do his homework. He must cultivate a flair for spotting the logical loophole, the invalid clinical trial, the unreliable or meaningless testimonial, the unneeded improvement and the unlikely claim. Above all, he must develop greater resistance to the lure of the fashionable and the new.
- Pierre R. Garai (advertising executive) 1963